276 related articles for article (PubMed ID: 7859739)
1. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.
Parry D; Bates S; Mann DJ; Peters G
EMBO J; 1995 Feb; 14(3):503-11. PubMed ID: 7859739
[TBL] [Abstract][Full Text] [Related]
2. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
Lukas J; Parry D; Aagaard L; Mann DJ; Bartkova J; Strauss M; Peters G; Bartek J
Nature; 1995 Jun; 375(6531):503-6. PubMed ID: 7777060
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines.
Ragione FD; Russo GL; Oliva A; Mercurio C; Mastropietro S; Pietra VD; Zappia V
J Biol Chem; 1996 Jul; 271(27):15942-9. PubMed ID: 8663131
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
[TBL] [Abstract][Full Text] [Related]
5. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
6. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P
Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707
[TBL] [Abstract][Full Text] [Related]
7. Mutations associated with familial melanoma impair p16INK4 function.
Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.
Parry D; Mahony D; Wills K; Lees E
Mol Cell Biol; 1999 Mar; 19(3):1775-83. PubMed ID: 10022865
[TBL] [Abstract][Full Text] [Related]
9. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.
Guan KL; Jenkins CW; Li Y; Nichols MA; Wu X; O'Keefe CL; Matera AG; Xiong Y
Genes Dev; 1994 Dec; 8(24):2939-52. PubMed ID: 8001816
[TBL] [Abstract][Full Text] [Related]
10. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells.
Sandhu C; Garbe J; Bhattacharya N; Daksis J; Pan CH; Yaswen P; Koh J; Slingerland JM; Stampfer MR
Mol Cell Biol; 1997 May; 17(5):2458-67. PubMed ID: 9111314
[TBL] [Abstract][Full Text] [Related]
12. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
13. v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity.
Clark W; Black EJ; MacLaren A; Kruse U; LaThangue N; Vogt PK; Gillespie DA
Mol Cell Biol; 2000 Apr; 20(7):2529-42. PubMed ID: 10713176
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1.
Doki Y; Imoto M; Han EK; Sgambato A; Weinstein IB
Carcinogenesis; 1997 Jun; 18(6):1139-48. PubMed ID: 9214595
[TBL] [Abstract][Full Text] [Related]
15. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
Khleif SN; DeGregori J; Yee CL; Otterson GA; Kaye FJ; Nevins JR; Howley PM
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4350-4. PubMed ID: 8633069
[TBL] [Abstract][Full Text] [Related]
17. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano M; Hannon GJ; Beach D
Nature; 1993 Dec; 366(6456):704-7. PubMed ID: 8259215
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
19. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.
Hirai H; Roussel MF; Kato JY; Ashmun RA; Sherr CJ
Mol Cell Biol; 1995 May; 15(5):2672-81. PubMed ID: 7739547
[TBL] [Abstract][Full Text] [Related]
20. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma.
Easton J; Wei T; Lahti JM; Kidd VJ
Cancer Res; 1998 Jun; 58(12):2624-32. PubMed ID: 9635589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
